Effects of in vitro and in vivo exposure to doxorubicin (adriamycin) on caffeine-induced Ca2+ release from sarcoplasmic reticulum and contractile protein function in 'chemically-skinned' rabbit ventricular trabeculae

Japanese Journal of Pharmacology

Volumn 76, Issue 4, 1998, Pages 405-413

  Takahashi, Shun Suke ^a   Denvir, Martin A ^b   Harder, Lisbet ^c   Miller, David J ^d   Cobbe, Stuart M ^b   Kawakami, Midori ^a   MacFarlane, Niall G ^d   Okabe, Eiichiro ^a  

^a KANAGAWA DENTAL COLLEGE   (Japan)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Calcium sensitivity; Doxorubicin; Myofilament; Sarcoplasmic reticulum; Ventricular trabeculae (rabbit)

Indexed keywords

CALCIUM CHANNEL; CALCIUM ION; CONTRACTILE PROTEIN; DOXORUBICIN; RYANODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CARDIOTOXICITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HEART VENTRICLE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; RABBIT; SARCOPLASMIC RETICULUM;

EID: 0031981552     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.76.405     Document Type: Article

References (29)

1. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P and Ross AM: Acute arrhythmogenicity of doxorubicin administration. Cancer 60, 1213-1218 (1987)
2. Singal PK, Deally CMR and Weinberg LE: Sub-cellular effects of doxorubicin in the heart: a concise review. J Mol Cell Cardiol 19, 817-828 (1987)
3. Dodd DA, Atkinson JB, Olson RD, Buck S, Cusack BJ and Fleischer S: Doxorubicin cardiomyopathy is associated with a reduction in the calcium release channel of the sarcoplasmic reticulum in a chronic rabbit model. J Clin Invest 91, 1697-1705 (1993)
4. Bers DM: Excitation-Contraction Coupling and Cardiac Contractile Force. p 152, Kluwer Academic Publishers, Boston/Dordrecht/Lancaster (1991)
5. Applefielg MM and Egorin MJ: The anthracycline antibiotics depress left ventricular contractility: a clinical fact or a laboratory fancy? Int J Cardiol 6, 351-353 (1984)
6. +-adenosine triphosphate. J Pharmacol Exp Ther 214, 368-374 (1980)
7. Brown KA, Blow AJ, Weiss RM and Stewart JA: Acute effects of doxorubicin on human left ventricular systolic and diastolic function. Am Heart J 118, 979-982 (1989)
8. Harrison SM, Lamont C and Miller DJ: Hysteresis and the length dependence of calcium sensitivity in cardiac muscle. J Physiol (Lond) 401, 115-143 (1988)
9. Miller DJ and Smith GL: EGTA purity and the buffering of calcium ions in physiological solutions. Am J Physiol 246, C160-C166 (1984)
10. Morton DB and Griffiths PH: Guidelines on the recognition of pain, distress and discomfort in experimental animals and a hypothesis for assessment. Vet Res 116, 4131-4136 (1985)
11. Pye MP, Black M and Cobbe SM: Comparison of in vivo and in vitro haemodynamic function in experimental heart failure: use of echocardiography. Cardiovasc Res 31, 873-881 (1996)
12. Brown KM and Dennis JS: Derivative free analogues of the Levenberg-Marquadt and Gauss algorithms for non-linear least square approximation. Numer Math 18, 283-297 (1972)
13. Buja LM, Ferrans VJ, Mayer RJ, Robert WC and Henderson ES: Cardiac ultrastructural changes induced by daunorubicin therapy. Cancer 32, 771-778 (1973)
14. Holmberg SRM and Williams AJ: Patterns of interaction between anthraquinone drugs and the calcium-release channel from cardiac sarcoplasmic reticulum. Circ Res 67, 272-283 (1990)
15. Bers DM: Ryanodine and Ca-content of cardiac SR assessed by caffeine and rapid cooling contractures. Am J Physiol 253, C408-C415 (1987)
16. Okabe E, Odajima C, Taga R, Kukreja RC, Hess ML and Ito H: The effect of oxygen free radicals on calcium permeability and calcium loading at steady state in cardiac sarcoplasmic reticulum. Mol Pharmacol 34, 388-394 (1988)
17. Okabe E, Sugihara M, Tanaka K, Sasaki H and Ito H: Calmodulin and free oxygen radical interaction with steady-state calcium accumulation and passive calcium permeability of cardiac sarcoplasmic reticulum. J Pharmacol Exp Ther 250, 286-292 (1989)
18. Olson RD and Mushlin PS: Doxorubicin cardiotoxicity: analysis of prevailing hypothesis. FASEB J 4, 3076-3086 (1990)
19. Boucek RJ, Olsen RD, Brenner DE, Ogunbunmi EM, Inui M and Fleischer S: The major metabolite of doxorubicin is a potent inhibitor of membrane associated ion pumps. J Biol Chem 262, 15851-15856 (1987)
20. Pessah IN, Durie EL, Schiedt MJ and Zimanyi I: Anthraquinone-sensitized calcium release channel from rat cardiac sarcoplasmic reticulum: possible receptor-mediated mechanism of doxorubicin cardiomyopathy. Mol Pharmacol 37, 503-514 (1990)
21. Okabe E, Kuse K, Sekishita T, Suyama N, Tanaka K and Ito H: The effect of ryanodine on oxygen free radical-induced dysfunction of cardiac sarcoplasmic reticulum. J Pharmacol Exp Ther 256, 868-875 (1991)
22. 2+ -release chan3 nel. Am J Physiol 253, C364-C368 (1987)
23. 2+ release channel of sarcoplasmic reticulum. J Biol Chem 261, 6300-6306 (1986)
24. 2+ release channel complex of skeletal muscle sarcoplasmic reticulum: evidence for a cooperatively coupled, negatively charged homotetramer. J Biol Chem 264, 16776-16785 (1989)
25. Shenasa H, Calderone A, Vermeulen M, Paradis P, Stephens H, Cardinale R, De Champlain J and Rouleau JL: Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium. Cardiovasc Res 24, 591-604 (1990)
26. Billingham ME, Mason JW, Bristow MR and Daniels JR: Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 62, 865-872 (1978)
27. 2+ binding and lipid peroxidation but depresses myocardial function. Am J Physiol 250, H419-H425 (1986)
28. Jensen RA: Doxorubicin cardiotoxicity: contractile changes after long-term treatment in the rat. J Pharmacol Exp Ther 236, 197-203 (1986)
29. Doroshow JH: Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res 43, 460-472 (1983)